新BCV:一种新型细菌液体复合疫苗,用于增强树突细胞介导的免疫反应,对抗肺癌

Zilong Zhu1, Zhuze Chu1, Fei Fei1

  • 1The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.

Vaccines
|January 24, 2025
PubMed
概括

新型细菌复合疫苗Neo-BCV通过促进树突细胞成熟和抑制JAK2-STAT3通路来增强肺癌中的抗瘤免疫力. 这一策略为癌症免疫治疗提供了一个有前途的新方法.